Allergan cites DTC spending as factor in strong Q2 results

Share this article:
Allergan cited strong spending behind DTC and detailing as factors in reporting stronger-than-expected Q2 results. The firm saw solid gains in its eyecare products, breast implants, medical devices for obesity and Botox for a 23% gain over Q2 2006.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union